Cefepime chloride

Cefepime (BMY-28142) chloride is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime chloride shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime chloride induces neurotoxicity[1][2][3][4].

Research Areas >> Infection

Cefepime chloride exerts its antibacterial effects by binding to penicillin-binding proteins[2].

Cefepime chloride (80 mg/kg; i.p.) significantly increases the half-life and mice surviveed[4]. Animal Model: Male CD-1 mice[4] Dosage: 80 mg/kg Administration: I.p. Result: Significantly prolonged the half-life of cefepime and all mice survived at 18-22 mg/kg cisplatin, and when pretreatment with 26 mg/kg cisplatin significantly decreased survival with the half-life of cefepime was not significantly longer than of 18 mg/kg cisplatin.

[1]. Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7(5):338-48.

[2]. Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47(3):471-505.

[3]. Payne LE, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1.

[4]. Máthé A, et al. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006 Jul;40(3):296-300.